Combination of LowDose Epigenetic Modifiers and TIC10 for the Activation of Antitumor Immunity and Inhibition of Tumor Growth in Gastrointestinal Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.71061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jianling Zou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Epigenesis, Genetic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cytotoxic agents remain the mainstay treatment for advanced gastrointestinal cancer. However, the number of cytotoxic agents is limited, and the treatment effect is not satisfactory. Therefore, new agent and combination strategies are to be explored.
Methods
The antitumor efficacy of low‐dose epigenetic modifiers (LD‐EMs) of 5‐azacytidine and entinostat, cytotoxic agents of paclitaxel, cisplatin, oxaliplatin, 5‐fluorouracil, and a novel cytotoxic agent TIC10, and the combination of LD‐EMs and cytotoxic agents was investigated in vivo. Flow cytometry and immunohistochemistry were conducted to analyze the immune phenotype in the tumor microenvironment. The proliferation and apoptosis analyses were performed in vitro.
Results
LD‐EM therapy demonstrated superior tumor inhibition compared with commonly used chemotherapy in gastrointestinal cancer. A novel cytotoxic agent TIC10 resulted in weak to moderate tumor growth inhibition (TGI). LD‐EMs exhibited a more pronounced antitumor effect than TIC10 alone (CT26: TGI of 74.5% vs. 46.2%, respectively; p < 0.05; HNM007: TGI of 52.0% vs. 21.4%, respectively; p < 0.05; AKR: TGI of 53.8% vs. 10.1%, respectively; p < 0.05). The combination of TIC10 and LD‐EMs led to a more pronounced tumor reduction with tolerable toxicity. Analysis of the immune profiles showed increased percentages of CD45 + lymphocytes, CD3 + and CD8+ T cells, M1 macrophages, and dendritic cells, whereas decreased percentages of M2 macrophages and myeloid‐derived suppressor cells under treatment with LD‐EMs and combination therapy. Mechanistic studies revealed that LD‐EMs activated the RIG‐I–MAVS pathway, stimulated type I interferon responses, and subsequently promoted chemokine secretion. In contrast, TIC10 suppressed cell viability and induced cell apoptosis.
Conclusions
LD‐EMs remodeled the tumor microenvironment to an immune‐promoting environment. Although TIC10 could suppress cell viability and induce cell apoptosis. A combination of LD‐EMs and TIC10 indicated a rational strategy through complementary mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Jilin, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Otolaryngology-Head and Neck Surgery, Otolaryngology Institute of Shanghai JiaoTong University, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Ch…
ORCID-Profile: Jianling Zou, Jinjia Chang, Wenhua Li, Weijian Guo, Zhiyu Chen
Förderung
- Wu Jieping Medical Foundation
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Zou, J., Yang, W., Li, S., Liu, F., Chang, J., Li, W., Huang, M., Zhu, X., Zou, J., Guo, W., & Chen, Z. (2025). Combination of LowDose Epigenetic Modifiers and TIC10 for the Activation of Antitumor Immunity and Inhibition of Tumor Growth in Gastrointestinal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71061
Vancouver
Zou J, Yang W, Li S, Liu F, Chang J, Li W, et al. Combination of LowDose Epigenetic Modifiers and TIC10 for the Activation of Antitumor Immunity and Inhibition of Tumor Growth in Gastrointestinal Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71061
BibTeX
@article{Zou2025,
author = {Zou, Jianling and Yang, Wentao and Li, Shuang and Liu, Fei and Chang, Jinjia and Li, Wenhua and Huang, Mingzhu and Zhu, Xiaodong and Zou, Jianyin and Guo, Weijian and Chen, Zhiyu},
title = {Combination of LowDose Epigenetic Modifiers and TIC10 for the Activation of Antitumor Immunity and Inhibition of Tumor Growth in Gastrointestinal Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71061}
}
EUVIMED